PMC:7073332 / 1204-1603 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"54","span":{"begin":65,"end":70},"obj":"Species"},{"id":"55","span":{"begin":304,"end":309},"obj":"Species"},{"id":"61","span":{"begin":35,"end":39},"obj":"Species"},{"id":"62","span":{"begin":116,"end":120},"obj":"Species"},{"id":"63","span":{"begin":267,"end":271},"obj":"Species"},{"id":"65","span":{"begin":383,"end":392},"obj":"Chemical"}],"attributes":[{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:694448"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:694448"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:694448"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D020123"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"imity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus d"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":147,"end":156},"obj":"Body_part"},{"id":"T7","span":{"begin":247,"end":251},"obj":"Body_part"},{"id":"T8","span":{"begin":310,"end":314},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"imity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus d"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":65,"end":70},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T5","span":{"begin":247,"end":251},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T6","span":{"begin":304,"end":320},"obj":"http://www.ebi.ac.uk/cellline#human_cell_line"}],"text":"imity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus d"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":18,"end":22},"obj":"Chemical"},{"id":"T16","span":{"begin":134,"end":139},"obj":"Chemical"},{"id":"T17","span":{"begin":147,"end":156},"obj":"Chemical"},{"id":"T18","span":{"begin":158,"end":172},"obj":"Chemical"},{"id":"T19","span":{"begin":178,"end":187},"obj":"Chemical"},{"id":"T20","span":{"begin":242,"end":246},"obj":"Chemical"},{"id":"T21","span":{"begin":358,"end":362},"obj":"Chemical"},{"id":"T22","span":{"begin":383,"end":392},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_50667"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_9168"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_9168"}],"text":"imity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus d"}